Kadmon Holdings (Kadmon Holdings) Debt-to-Equity : 18.61 (As of Sep. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings Debt-to-Equity?

Kadmon Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $4.56 Mil. Kadmon Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $245.41 Mil. Kadmon Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2021 was $13.43 Mil. Kadmon Holdings's debt to equity for the quarter that ended in Sep. 2021 was 18.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kadmon Holdings's Debt-to-Equity or its related term are showing as below:

KDMN' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.75 Med: 0.2 Max: 19.17
Current: 18.61

During the past 7 years, the highest Debt-to-Equity Ratio of Kadmon Holdings was 19.17. The lowest was -3.75. And the median was 0.20.

KDMN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs KDMN: 18.61

Kadmon Holdings Debt-to-Equity Historical Data

The historical data trend for Kadmon Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings Debt-to-Equity Chart

Kadmon Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Equity

Get a 7-Day Free Trial

-1.21

19.17

0.31

0.14

0.20

Kadmon Holdings Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Debt-to-Equity	Get a 7-Day Free Trial															0.17	0.20	4.30	7.49	18.61

Competitive Comparison of Kadmon Holdings's Debt-to-Equity

For the Biotechnology subindustry, Kadmon Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kadmon Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadmon Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kadmon Holdings's Debt-to-Equity falls into.

Kadmon Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kadmon Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.922	+	16.938)	/	116.023
	=	0.20

Kadmon Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.56	+	245.409)	/	13.432
	=	18.61

Kadmon Holdings (NAS:KDMN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kadmon Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadmon Holdings (Kadmon Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East 29th Street, New York, NY, USA, 10016

Website

https://www.kadmon.com

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Executives

Harlan Waksal	director, officer: President, CEO	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer	director	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris	director	103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan	officer: Executive Vice President, CMO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan	officer: EVP, Chief Financial Officer	450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver	officer: Principal Accounting Officer, Controller	450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss	officer: EVP, General Counsel, Chief Compliance Officer	450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	other: Former 10% owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon	officer: Exec VP, GC, Chief Admin, Comp	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016